Title:

Evaluation of nanopore sequencing on polar bodies for routine PGT-A

Running title:

Nanopore aneuploidy screening on polar bodies

Authors:

Anna Oberle[1], Franziska Hanzer[1], Felix Kokocinski[2], Anna Ennemoser[1], Luca Carli[1], Enrico Vaccari[1], Markus Hengstschläger[1], Michael Feichtinger[1*]

Affiliation:

1 Wunschbaby Institut Feichtinger, Lainzer Straße 6, 1130 Vienna, Austria

2 Gene-Test Bioinformatics Solutions, Jakob-Müller-Str. 16, 68623 Lampertheim, Germany

*Corresponding author: Michael Feichtinger, MD, PhD, EFRM-ESHRE/EBCOG,

michael.feichtinger@wunschbaby.at, +43 1 8777775, Lainzerstrasse 6, 1130 Vienna, Austria

Abstract

STUDY QUESTION:

Is nanopore sequencing for PGT-A analysis of pooled polar bodies a reliable, fast, and cost-effective method and applicable for routine diagnostics in human reproductive care?

SUMMARY ANSWER:

Nanopore sequencing of pooled polar bodies (PB) revealed high concordance rate with traditional array comparative genomic hybridization (aCGH) analysis and the nanopore sequencing workflow was fast (feasible in under 5 hours) and cost-effective (100-150€ per sample), allowing fresh embryo transfer.

WHAT IS KNOWN ALREADY:

PGT-A using PB biopsy derives a clinical benefit by reducing number of embryo transfers and miscarriage rates but is currently not cost-efficient. Results are often unclear and require expert review. Nanopore sequencing technology opens possibilities by providing cost-efficient, fast sequencing results with uncomplicated sample preparation workflows. Interrogating the polar bodies avoids harming the embryo itself and is the only option for PGT-A in some jurisdictions.

STUDY DESIGN, SIZE, DURATION:

In this prospective clinical trial, 102 pooled PB samples from 20 patients treated for infertility between March and December 2022 were analyzed for aneuploidy using nanopore sequencing technology and compared with aCGH results generated as part of the clinical routine. All patients participating in this trial were treated for infertility at 'Wunschbaby Institut Feichtinger' (WIF) in Vienna and chose aneuploidy screening of their polar bodies. All patients provided written informed consent.

PARTICIPANTS/MATERIALS, SETTING, METHODS:

PB samples were analyzed by aCGH for routine PGT-A. Aliquots of whole-genome amplified DNA were anonymized and prepared for sequencing by end-prepping, barcoding and adapter ligation. Samples were pooled equimolar for sequencing on a Nanopore MinION machine. Samples were sequenced for up to 9 hours for 6 pooled PB samples. Whole-chromosome copy-numbers were called by a custom bioinformatic analysis software after alignment and pre-processing. Automatically called results were compared to aCGH results.

MAIN RESULTS AND THE ROLE OF CHANCE:

In total, 99 pooled polar body samples were compared, three samples were excluded because of failed or uninterpretable results. Overall, the Nanopore sequencing workflow showed high concordance rates with aCGH: 96 of 99 samples were consistently detected as euploid or aneuploid (concordance=97%, specificity = 0.957, sensitivity = 1.0, PPV = 0.906, NPV = 1.0) and 91 samples showed a fully concordant karyotype (92%). Chromosomal aneuploidies analyzed in this trial covered all 23 chromosomes with 98 trisomies, 97 monosomies in 70 aCGH samples.

Detailed calculation of time and cost for the nanopore sequencing workflow was performed for different scenarios. Time calculation revealed that the whole nanopore workflow is feasible in under 5 hours (for one sample) with maximum time of 16 hours (for 12 samples in parallel). This enables fresh PB euploid embryo transfer. Material cost for the whole workflow range between 100€ and 150€, including sequencing cost of only 40€ per sample, resulting in cost-efficient aneuploidy screening.

LIMITATIONS, REASONS FOR CAUTION:

For some samples, the reference result remained unclear, due to increased noise and limited resolution of the aCGH method. In particular, the small chromosomes show higher variability in both platforms and manual review is often required. A larger study with follow-up data or a clinical non-selection trial would be beneficial for increased confidence.

WIDER IMPLICATIONS OF THE FINDINGS:

This is the first clinical study, systematically comparing nanopore sequencing for aneuploidy of pooled polar bodies with standard detection methods. High concordance rates confirmed feasibility of nanopore technology for this application. Additionally, the fast and cost-efficient sequencing workflow reveals clinical utility of this technology, making polar body PGT-A clinically attractive.

STUDY FUNDING/COMPETING INTEREST(S):

The study was funded by the Wunschbaby Institut Feichtinger, Dr. Wilfried Feichtinger GmbH. The authors declare no competing conflict of interest.

TRIAL REGISTRATION NUMBER: Not available

Keywords

PGT-A, Polar Body Biopsy, Nanopore Sequencing, Oxford Nanopore Technology, Cost effective PGT-A

Introduction

With increasing female age, the probability for aneuploid embryos increases and with it the risk of age-
related infertility, abortions and children born with trisomy 21 (Franasiak et al., 2014). Early pregnancy
loss and spontaneous abortions are most frequently caused by chromosomal abnormalities of the
embryo (Petracchi et al., 2009). In contrast to maternal age, paternal age plays a minor role for
chromosomal abnormalities (Fonseka and Griffin, 2011). Preimplantation-genetic testing for
aneuploidy (PGT-A) is used to screen for unbalanced chromosomal distributions in embryos and can
therefore reduce miscarriage rates and improve pregnancy and life-birth rates per embryo-transfer,
especially in patients with advanced-maternal age (Feichtinger et al., 2015; Rubio et al., 2017).

DNA analyzed in PGT-A can originate from trophectoderm cells, blastomere cells or polar bodies. All
three sources have advantages and specific limitations. While polar body analysis allows the detection
of meiotic maternal aneuploidies only, the analysis of trophectoderm biopsy (TEB) and blastomere
biopsy can detect embryogenic aneuploidies. However, blastomere biopsy can possibly damage the
embryo (Cohen et al., 2007; Scott et al., 2013) and was shown to provide limited clinical benefit
(Mastenbroek et al., 2007). Blastomere biopsy is therefore not commonly performed anymore. In TEB
analysis, which is currently seen as the gold standard for PGT-A, diagnosed trophectoderm
aneuploidies might differ from embryogenic material of the inner cell mass due to mosaicisms (Viotti
et al., 2021). Embryos classified as aneuploid or mosaic by TEB can lead to euploid, healthy life-births,
indicating discordances between inner cell mass and trophectoderm or self-repair mechanisms (Greco
et al., 2015; Treff and Marin, 2021).

In contrast, PGT-A using polar body biopsy leaves less room for interpretation, since mitotic errors in
cell division leading to mosaicisms are not detected here. In a large multicenter randomized clinical
trial ('ESHRE Study into the Evaluation of oocyte Euploidy by Microarray analysis', ESTEEM trial), PGT-
A using polar body biopsy was shown to significantly reduce the number of embryo transfer needed
for live birth, reduce number of cryopreserved embryos and reduce miscarriage rates (Verpoest et al.,
2018). These findings highlight the clinical benefit for PGT-A using polar body biopsy. In contrast to
PGT-A using TEB, polar body biopsy allows fresh embryo transfer and can avoid freeze-all procedures.
Additionally, due to legal restrictions for TEB analysis in several European countries, polar body biopsy
is performed frequently in countries like Germany or Austria (Hengstschläger and Feichtinger, 2005;
Ven et al., 2008).

However, polar body analysis was stated not to be cost effective using average published costs for
PGT-A and IVF/ICSI treatment neither specifically in Germany nor in a universally applicable scenario
using data of the ESTEEM trial (Neumann and Griesinger, 2020; Neumann et al., 2020). Average cost
per patient (five analyzed oocytes) was stated with around US$ 5.200 while the threshold for PGT-A to
be cost-effective was calculated between US$ 285 (low-cost scenario) and US$ 2.204 (high-cost
scenario) (Neumann et al., 2020). Therefore, lowering the cost for polar body PGT-A and PGT-A in
general is an important goal to improve patient acceptance and to access the clinical benefit for this
intervention.

PGT-A is often performed using short-read next-generation sequencing (NGS), which requires high
initial investment costs and high running expenses. Third-generation sequencing using nanopores is a
novel technology with the potential to perform sequencing in a fast, easy, and cost-effective way,
enabling application even in small and less well-financed clinics (Cabibbe et al., 2020). Continuous
development of the technology led to significant improvements in sequencing quality, accuracy, flow
cells and data analysis (Amarasinghe et al., 2020; Jain et al., 2018).

Feasibility of long-read nanopore sequencing for PGT was mainly shown for structural variants and
monogenetic disease (Cretu Stancu et al., 2017; Hu et al., 2019; Madjunkova et al., 2020; Margolis et

al., 2021; Pei et al., 2022), which comes with high costs and is far from clinical routine (Margolis et al., 2021). PGT-A from TEB samples using nanopore sequencing was first demonstrated in a small pilot study, where 9 TEB samples were analyzed with an optimized nanopore protocol and compared to cytogenetic analysis using NGS (Wei et al., 2018). A follow-up study from the same group compared their optimized nanopore aneuploidy analysis of 52 chorionic villi samples, 50 amniotic fluid samples, 64 placental or fetal tissue samples and 52 TEB samples with standard NGS PGT-A screening (Wei et al., 2022). Overall, the authors saw very good concordance rates with 100% concordant results for chorionic villi, amniotic fluid and placenta or fetal tissue samples. TEB samples showed one false negative result with a trisomy 21 not being detected by their nanopore sequencing protocol. The optimized nanopore workflow was notably faster (2-6 hours) and more cost-effective (around 50 US$ sequencing cost per sample) compared to traditional NGS screening. Additionally, the workflow was verified by independently trained laboratory technicians with 100% concordance (Wei et al., 2022). This was the first systematic clinical evaluation of nanopore sequencing for aneuploidy including PGT-A with TEB samples. However, due to limited sample number and missing independent external verification of PGT-A samples in this study, further clinical studies are needed to transfer the technology into clinical PGT-A routine analysis.

In the present study, pooled polar bodies from 99 oocytes were analyzed using nanopore sequencing and compared to results generated as part of the clinical routine using array comparative genomic hybridization (aCGH). This is the first study that systematically analyses aneuploidy from polar body samples using nanopore sequencing technology including detailed cost analysis of the nanopore sequencing workflow.

Material and Methods

Study design and sampling

The present study was designed as a prospective comparative study for aneuploidy analysis of 100
pooled polar bodies using the novel nanopore sequencing technology in comparison with standard
routine analysis by aCGH. All participating patients were treated for infertility at the 'Wunschbaby
Institut Feichtinger' (WIF) in Vienna and chose to perform polar body analysis for aneuploidy of their
oocytes. All patients included in this study provided written informed consent. The study was approved
by the Ethic Committee of the Medical University Vienna (EK-1249/2022). After oocyte pick-up and
fertilization by intracytoplasmic sperm injection (ICSI), both polar bodies were taken simultaneously
16 to 18 hours after fertilization and placed in a sterile PCR tube with 2.5 µl of fresh, sterile phosphate-
buffered saline (PBS). Opening of the zona pellucida was performed using RI Saturn 5 Active^{TM}
(Research Instruments Ltd, UK). Polar body samples were frozen at -20°C and transported to an
external genetic diagnostic laboratory for routine analysis.

DNA Amplification and reference analysis

PGT-A routine analysis of pooled polar bodies was performed after the standard GentiSure Pre-Screen
Kit for Single Cell Analysis Kit (Agilent Technologies, USA) protocol, including Whole Genome
Amplification (WGA) with REPLI-g Single Cell Kit using a phi29 polymerase process (QIAGEN, Germany),
Fluorescent Labeling and CGH Microarray. This standard protocol was adapted for Polar Body Diagnosis
(PBD). Around 5µg of WGA aliquots from pooled polar body samples were anonymized and used for
nanopore sequencing.

Nanopore Library Preparation

The library preparation workflow and bioinformatic data analysis pipeline for polar body nanopore
sequencing for aneuploidy was set-up and optimized in a pre-clinical study using sequencing of known
euploid and aneuploid genomic DNA and single-cells from fibroblast cell lines (Coriell, USA) (Oberle et
al., 2022).

After receiving anonymized WGA amplified DNA samples, quality was confirmed by 0.8% agarose gel
electrophoresis (Thermo Fisher Scientific, USA) and quantity was measured by Qubit 4 fluorometer
(Thermo Fisher Scientific, Singapore). Then WGA DNA was purified using gDNA Clean & Concentrator-
25 columns (Zymo Research, USA) with elution in 100µl nuclease-free Water (Ambion by Life
Technologies, USA).

As part of the protocol optimization, around 1.5µg of purified DNA was prepared for some samples by
digestion of single-stranded regions using T7 Endonuclease I (New England Biolabs (NEB), UK) to
reduce or remove branched structures which were introduced during amplification. DNA was purified
using gDNA Clean & Concentrator-25 columns (Zymo Research, USA) and eluted in 50µl nuclease-free
water.

For library preparation, the Oxford Nanopore Technology (ONT, UK) Kits 'Ligation Sequencing Kit' (SQL-
LSK109) and 'Native Barcoding Expansion' (EXP-NBD104) were used according to manufacturer's
recommendations.

Briefly, for DNA repair and end-preparation, 1-1.5µg purified DNA in 48µl nuclease-free water was
added to 2µl NEBNext® FFPE DNA Repair Mix with 3.5µl buffer and 3µl NEBNext® Ultra^{TM} II End-prep
Enzyme Mix with 3.5µl buffer (all from NEB, UK) and incubated for 5 minutes at 20°C plus 5 minutes at
65°C. The end-prepped DNA was purified using DNA Clean & Concentrator-5 columns (Zymo Research)

with elution in 25µl nuclease-free water and purified DNA concentration was measured by Qubit
fluorometer.

For native barcode ligation, around 500 to 700 ng end-prepped, purified DNA was diluted in 22,5µl
nuclease-free water and 2,5µl Native Barcode (ONT) plus 25µl Blunt/TA Ligase Master Mix (NEB) was
added, followed by 10 minutes incubation at room temperature. Barcoded DNA was purified using
DNA Clean & Concentrator-5 columns (Zymo Research), eluted in 26µl nuclease-free water and
concentration was measured using Qubit fluorometer. Purified, barcoded DNA samples for one
sequencing run were pooled equimolar in one tube and diluted in 65µl with nuclease-free water.

Pooled barcoded samples for one sequencing run (between 4 to 8 samples, see Suppl. Table 1) were
ligated to AMII adapters (ONT) by adding 5µl AMII adapter, 20µl NEBNext® Quick Ligation Reaction
Buffer and 10µl Quick T4 DNA Ligase (both NEB) and incubated for 10 minutes at room temperature.
For the final clean-up, SPRIselect beads (Beckman Coulter, USA) were utilized to ensure elimination of
small DNA fragments. 50µl (=0.5x) SPRIselect beads were added to the ligation mix, incubated for 5
minutes at room temperature. Beads bound to DNA were pelleted on a magnetic stand, supernatant
was removed, and pelleted beads were washed two times with Short Fragments Buffer (SFB, ONT).
After the second wash, all remaining SFB was removed, and beads were dried briefly. Dried beads were
resuspended thoroughly with 15µl Elution Buffer (ONT) and incubated at room temperature for 10
minutes. Beads were pelleted and purified DNA library was transferred into a clean tube and quantified
using a Qubit fluorometer.

Nanopore sequencing

The sequencing-ready library was primed and loaded on a MinION R9.4 flow cell (FLO-MIN106D, ONT)
according to manufactures recommendation using 25-30 fmol DNA library. Sequencing was performed
on MinION Mk1C with simultaneous base calling using standard base calling settings and quality
threshold (minimum Q-score) of 8. Sequencing time was adapted according to number of samples
pooled and quality of the flow cell (pores available) with average sequencing time of around 9 hours
for 6 pooled PB samples resulting in a median number of 105,670 reads (after pre-processing, stdev=
76,444) and 210 Mbases (stdev=100) generated per sample (detail sequencing constitution, time and
output in Suppl. Table 1).

Data analysis

Nanopore's *MinKNOW* software system controls the raw data acquisition, performing basecalling and
demultiplexing with *Guppy* as well as FASTQ file creation. Following on, a data analysis pipeline was
applied, developed for long read-based PGT-A data using standard bioinformatics tools and custom
software scripts. The specific processing steps are described in the following.

Primary data analysis consisted of read cleaning with *Porechop* (Porechop, RRID:SCR_016967) and
Nanofilt (De Coster et al., 2018), alignment to the human genome GRCh38 with *minimap2* (Li, 2018)
and creation of BAM files with *samtools* (Li et al., 2009). Secondary processing steps made use of the
QDNAseq R software package (Scheinin et al., 2014) and include binning of reads using a custom 500
kb bin matrix, GC content and mappability correction, median and reference normalisation,
smoothing, segmentation and copy-number calling. A set of five samples were used as a combined
reference to capture experiment-specific bias. They represented the first few samples of the study
with a representative profile and without whole-chromosome copy-number changes as assessed by
aCGH. Further processing was performed to filter and summarize the data, producing a report with
genome-wide copy-number plots, noise measurements and automatically detected changes per
chromosome and sample.

As quality measures of the nanopore sequencing samples, MAPD (Median of the Absolute values of all
Pairwise Differences) and noise (median standard deviation of normalised read counts within each
segment) values are reported for all chromosomes as well as for each sample and automatically plotted
in the chromosomal distribution plots. Samples resulting in a total noise value greater than 0.6 and
MAPD value greater than 1.7 were excluded from the comparison (Suppl. Table 1).

Results

Study design and nanopore sequencing workflow:

In this study, 102 pooled PB samples from 20 patients were analyzed for PGT-A by nanopore
sequencing and compared to clinical routine PGT-A analysis by aCGH. Medium age of all participating
patients was 40,5 years (from 35 to 46 years).

After PB biopsy 16-18 hours after fertilization, all pooled PB samples were frozen, shipped to the
genetic diagnostic laboratory and whole-genome amplification was performed. All samples were
successfully amplified while a negative control (culture medium) for each batch showed no
amplification and aCGH was performed for all 102 PB samples. WGA aliquots were anonymized and
used for nanopore sequencing. Schematic study design is shown in Figure 1.

Amplified PB samples were prepared for nanopore sequencing by DNA-repair, end-preparation,
Barcode ligation and Adapter ligation. Samples for one nanopore sequencing run were pooled and
sequenced on a MinION sequencing machine. For each sequencing run, between four and seven
samples were sequenced simultaneously. Flow cells were re-used for maximum of 12 samples. A
detailed list showing all sequencing runs and the respective samples is shown in Supplementary Table
1. The nanopore sequencing workflow, including data analysis and average time calculation is shown
in Figure 2.

Detailed time and cost calculation:

To evaluate if nanopore sequencing for PGT-A can be utilized in clinical routine, we performed a
detailed time and cost analysis for our nanopore sequencing workflow, which is listed in
Supplementary Tables 2 and 3. The nanopore sequencing workflow used in this study starting from
amplified DNA until ploidy result is feasible in one and a half hours with one sample being sequenced
separately. For 12 samples being sequenced in parallel, we recommend sequencing 6 samples on one
flow cell. Then, sample preparation, sequencing and data analysis is feasible in around 12 hours
(Supplementary Table 2). Amplification of the pooled polar bodies additionally take between 1.5 hours
and 4.5 hours per sample, depending on the kit used for WGA and the number of samples run in
parallel. In our study, WGA was performed using REPLIg Single Cell Kit (QIAGEN) with a 2.5 h
amplification protocol.

Material cost for the whole workflow, including WGA, sample preparation, sequencing and data
analysis range from 100€ until 220€ per sample. A detailed list of time and cost calculation for different
scenarios is shown in Supplementary Table 2 and 3. Initial investment cost for nanopore sequencing
can be neglected because prices for nanopore starter packages, where MinION sequencing machines
are included cover material costs.

Quality control and genome coverage for nanopore sequencing workflow:

In total three samples were excluded from the comparison due to failed or uninterpretable results.
Two samples (PB61, PB95) were excluded due to failed or uninterpretable aCGH (2 %) and one sample
(PB48) was excluded due to failed quality check after nanopore sequencing with noise and MAPD
values below quality threshold (1%).

Data analysis from nanopore sequencing results revealed medium sequencing output of 210 Mbases
and a median of 105,670 reads per sample (after pre-processing, 70 to 650 Mbases and 32,924 to

374,841 reads). A median of 3% (88 Mbases) of the genome was covered by one or more reads
(between 0.9 – 9.3%). With the 0.5 Mbases bin matrix applied in the analysis, a smoothing window of
6 bins and a calling limit of 20 bins, the application has a theoretical resolution of around 10 Mbases.
This is comparable with the common resolution for PGT-A using aCGH or NGS (6-10 Mbases) (Snider
et al., 2021). Average Q-score of all nanopore-sequenced samples was 8. Quality was additionally
verified in the bioinformatic data analysis pipeline by noise and MAPD values. Average noise of all
samples was 0.428 (between 0.230 and 0.724) and average MAPD was 1.164 (between 0.720 and
1.809). All noise and MAPD values are listed in Supplementary Table 1 and realtionship between both
quality measures is visualized in Supplementary Figure 1.

Comparison of PGT-A results from nanopore sequencing with routine aCGH results:

In total, 99 pooled PB samples for PGT-A screening were utilized in this study for comparison of ploidy
status by routine aCGH and by nanopore sequencing workflow. From these 99 samples, 29 were
detected euploid (29.3 %) and 70 were detected aneuploid (70.7 %) by aCGH reference. This is
expected, given the patient cohort with medium female age of 40.5 years. Nanopore sequencing
analysis detected 32 samples as euploid and 67 as aneuploid resulting in 97% concordance with aCGH
analysis and a sensitivity of 0.95, specificity of 1.0 with a positive predictive value (PPV) of 1.0 and a
negative predictive value (NPV) of 0.90 (Figure 1). Three samples detected as aneuploid using aCGH
revealed an euploid chromosomal pattern using nanopore sequencing. All three samples showed a
single aneuploid chromosome (+22, +19, -16, respectively) by aCGH and these elevations or reductions
were visible but below threshold at nanopore sequencing, as listed in Supplementary Table 1.

In total, aCGH analysis detected 195 aneuploid chromosomes in the 99 samples, with 98 trisomies and
97 monosomies covering all 23 chromosomes, shown in Figure 3. Counting the exact match (all
chromosomes concordant but assigning "multiple" to karyotypes with more than three aberrations) of
nanopore sequencing results with aCGH results, we found 91.9% concordance (91 of 99 samples
showing exact match). Segmental changes were not addressed in this study. For all samples, where
Endonuclease digest was performed following WGA, the results with Endonuclease digestion were
utilized for this comparison (see below). Example chromosomal distribution plots of euploid and
aneuloid detected samples, which are automatically created from bioinformatic data analysis pipeline
after nanopore sequencing are shown in Figure 4.

To assist the physicians and patients in the process of decision-making, a further critical evaluation of
euploid-detected PBs can be performed and marginal/borderline elevated or reduced chromosomes
can be mentioned together with the euploid result in the clinical report. Here, we performed manual
revision of all euploid-detected samples after nanopore sequencing and the additional information
about slightly elevated or reduced chromosomes can be found in Supplementary Table 1.

Endonuclease digestion step:

As part of this study, we evaluated the importance of an endonuclease digestion step. 28 samples were
run in parallel with and without endonuclease digestion step. While samples with a high signal to noise
ratio (between copy-number changes and the normal level) show matching results, the additional
digestion clearly reduces noise and improves calling for challenging cases. Reduction of average noise
and MAPD values, as well as improvements of sequencing-output per time is shown in Figure 5.
Detailed comparison of sequencing results with and without endonuclease digest is listed in
Supplementary Table 4. For the calculation of concordance between aCGH and nanopore sequencing,

results after Endonuclease digest were utilized for all these samples. For all new investigations we
recommend adding this step.

Discussion

The present study is the first study that systematically compares polar body PGT-A analysis using nanopore sequencing with routine aCGH analysis. PGT-A results on pooled polar bodies using novel nanopore sequencing analyses showed high concordance rates compared with routinely performed aCGH.

Even though PGT-A through trophectoderm biopsy can be regarded the gold standard of preimplantation genetic testing nowadays, polar body analysis has several advantages.

More and more patients undergoing assisted reproduction in Europe and the US are of advanced reproductive age and thus potentially benefitting from PGT-A (European IVF-monitoring Consortium (EIM) et al., 2017). However, those patients tend to have low to very low ovarian reserve leading to poor response to ovarian stimulation. Thus, those treatments often do not result in good quality blastocysts eligible for trophectoderm biopsy and cryopreservation. Furthermore, freeze-all strategies in normal and poor-responders have been shown to reduce cumulative ongoing pregnancy rates compared with fresh embryo transfers (Wong et al., 2021).

Polar body analysis allows fresh embryo transfer and reduces unnecessary lab procedures like extended blastocyst culture and cryopreservation of potentially aneuploid embryos. Since the polar bodies represent a byproduct of the oocyte, no essential structure of the future embryo is harmed. Even though polar body analysis covers only the maternal part of meiotic aneuploidies, those are thought to contribute to up to 99% of meiotic aneuploidies with only 1% paternal meiotic aneuploidies (Lodge and Herbert, 2020). Postzygotic mitotic aneuploidies on the other hand might result in mosaic embryos (Treff and Marin, 2021). Mosaic embryos have been shown to have the potential to result in healthy live births, questioning the sensitivity of trophectoderm biopsy and potentially leading to the discardment of healthy embryos diagnosed as aneuploid (Greco et al., 2015; Victor et al., 2019). Polar body analysis on the other hand is not challenged by mosaicism and therefore does not imply this risk.

Apart from medical considerations, polar body diagnosis might be applied in countries with legal restrictions to trophectoderm biopsy or embryo cryopreservation.

Polar body biopsy compared to untested embryo transfer has been shown to reduce miscarriage rates and to increase pregnancy and live birth rates per euploid transfer in patients of advanced maternal age (Feichtinger et al., 2015; Verpoest et al., 2018). However, up to very recently, polar body biopsy did not prove cost-efficient, resulting in significantly higher costs per patient and per live birth (Neumann et al., 2020).

The present study systematically compares PB PGT-A analysis using nanopore sequencing with routine aCGH analysis. The concordance rate between both technologies found in this study was 97% for euploid/aneuploid decision and 92% for exact match. These concordance rates are high, given the different nature of the methods and the delicate sample type of PB biopsy. Similar studies comparing different technologies for PGT-A analysis received slightly higher concordance rates (Kung et al., 2015; Sachdeva et al., 2017; Walters-Sen et al., 2021; Wei et al., 2022). However, genetic material utilized in these studies was originated from trophectoderm biopsy, which comprises significantly more genetic starting material than PB biopsy, resulting in more stable and uniform whole genome amplification. From 102 PB samples analyzed with nanopore sequencing in our study, 101 samples passed the quality threshold, indicating a high reliability of the technology.

In a comparable study using nanopore sequencing in comparison with standard clinical detection methods (NGS, FISH, aCGH), discordant aneuploidy results were re-examined and the initial nanopore sequencing results were confirmed in these samples, showing that even established clinical testing

methods like FISH or aCGH might result in misdiagnosis (Wei et al., 2022). Misdiagnosis of routine aCGH
PGT-A analysis has also been shown previously in a study comparing aCGH with NGS results (Sachdeva
et al., 2017). In the present study using material from pooled polar bodies, re-examination of aCGH
was not possible due to limited sample resource.

Independent of the technology, the analysis of chromosomal material is complicated by the different
characteristics of human chromosomes (Piovesan et al., 2019). The short chromosomes 19, 20, 21, 22
and Y provide limited material which leads to an increased variability in measurements. The GC-richest
chromosomes 16, 17, 19 and 22 often display increased levels of noise. Also chromosomes with
heterochromatic polymorphisms, like chromosomes 1, 9 and 16 differ due to normal, benign
variations in heterochromatin-content, which can be visualized by microscopy but is hard to interpret
in sequencing-based methods or aCGH (Hernandez-Nieto et al., 2021). In our study, the chromosomes
9, 19, 21 and 22 showed most discordances (Figure 3).

Nanopore sequencing has several advantages, compared to aCGH or NGS analysis, including but not
limited to the fast turnaround time, inexpensive sequencing, as well as small initial investment costs
needed. These advantages might lead to cost-efficient diagnostics for clinical applications. Time and
cost of nanopore sequencing for clinical reproductive healthcare has been reported in several
publications, but detailed statements on how these number can be achieved are often not stated
(Bartalucci et al., 2019; Cretu Stancu et al., 2017; Wei et al., 2018, 2022). Here, we provide detailed
insight in material costs and preparation, sequencing, and data analysis time for different scenarios
(Supplementary Table 2 and 3).

Several factors significantly influence the laboratory and sequencing time as well as material costs. The
main factor influencing the time per sample is the number of samples, that are prepared and
sequenced in parallel, mostly influencing sequencing time, but also sample preparation time. The main
factor influencing cost per sample is the sample throughput per year, because flow cell price changes
significantly with the number of flow cells purchased per year (between 450€ and 900€ per flow cell).
Here, we calculate with 48 flow cells per year (approximately 500 samples/year), leading to a flow cell
price of 475€ (ONT Store EU, visited in April 2023). Since flow cells can be re-used after sequencing,
sequencing price per sample does not change much with lower samples being sequenced in parallel.
For one sample, the whole analysis workflow, including WGA, library preparation, sequencing and data
analysis is possible in under 5 hours and for 12 samples being prepared in parallel, this workflow is
feasible in 14 to 16 hours (Supplementary Table 3), leading to same-day results.

The fact that nanopore sequencing, in contrast to aCGH or NGS applications, does not require high
initial investment costs, opens the possibility for decentralized diagnostic laboratories associated to
IVF clinics. With more, decentralized diagnostic laboratories, transportation of genetic material to
large, centralized laboratories is not necessary, again leading to faster turnaround-time. The fast
turnaround-time of the optimized nanopore sequencing workflow used in this study opens the
possibility for same-cycle transfer of euploid embryos, leading again to a cost reduction by reducing
freeze-all procedures and hormonal treatment for the embryo transfer, possibly leading to a shorter
time-to-pregnancy.

Another advantage of nanopore sequencing compared to aCGH or NGS is the high flexibility of the
sequencing method. Sequencing data as well as quality measures of the data generated, and the flow
cell health can be monitored in real-time during nanopore sequencing. If more data is required or
quality of the library is poor, sequencing can easily be prolonged or repeated on the same flow cell
until sufficient amount of data is generated. This can reduce the necessity to repeat uninterpretable
results and can reduce prolonged time-to diagnosis.

In our study, the data analysis pipeline automatically generates the sequencing plot with significantly abnormal chromosomes being highlighted and quality measures (noise and MAPD) are plotted for each chromosome. Example plots are shown in Figure 4. The karyotype is reported automatically according to the optimized bioinformatic pipeline. This automation together with the clear and easy-to-read karyotype plot makes the nanopore sequencing data very easy to read and understand. Interpretation of the results does not require years of expert knowledge and experience, which is often required for the interpretation of aCGH plots. The automated analysis pipeline is not dependent on subjective decision-making of the responsible geneticist or physician.

Nevertheless, following the clinical practice, we additionally performed manual review of all euploid-detected samples (Supplementary Table 1). This additional annotation about small chromosomal aberrations does not change the automatically reported result (euploid) but can be provided as additional information in the medical report. This report can facilitate the embryo prioritization and decision-making for the physician and the patients as part of their fertility treatment.

Taken together, pooled polar body nanopore sequencing revealed high concordance rates compared to conventional aCGH with minimized time and financial resources required.

Author's roles

AO, MF, and MH designed the study. AO optimized the nanopore sequencing workflow and supervised the experiments. FH performed the nanopore sequencing, FK performed data analysis. AO, FH, FK, MF, and MH interpreted the results. AO, FH, FK, and MF designed and wrote the manuscript. AE, LC, EV performed PB biopsies and provided insights in embryology. All authors approved the final version of the manuscript.

Acknowledgements

We would like to thank all patients participating in this study! We also thank all staff members from HLN Genetic GmbH for providing the reference samples and for the collaboration in this study.

Funding

The study was funded by the Wunschbaby Institut Feichtinger, Dr. Wilfried Feichtinger GmbH. No external funding was applied for this study.

Conflict of Interest

The authors declare no conflict of interest.

References

Amarasinghe, S.L., Su, S., Dong, X., Zappia, L., Ritchie, M.E., and Gouil, Q. (2020). Opportunities and challenges in long-read sequencing data analysis. Genome Biol. *21*.

Bartalucci, N., Romagnoli, S., Contini, E., Marseglia, G., Magi, A., Guglielmelli, P., Pelo, E., and Vannucchi, A.M. (2019). Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clin. Chem. *65*, 1604–1605.

Cabibbe, A.M., Spitaleri, A., Battaglia, S., Colman, R.E., Suresh, A., Uplekar, S., Rodwell, T.C., and Cirillo, D.M. (2020). Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J. Clin. Microbiol. *58*.

Cohen, J., Wells, D., and Munné, S. (2007). Removal of 2 cells from cleavage stage embryos is likely to reduce the efficacy of chromosomal tests that are used to enhance implantation rates. Fertil. Steril. *87*, 496–503.

De Coster, W., D'Hert, S., Schultz, D.T., Cruts, M., and Van Broeckhoven, C. (2018). NanoPack: visualizing and processing long-read sequencing data. Bioinformatics *34*, 2666–2669.

Cretu Stancu, M., van Roosmalen, M.J., Renkens, I., Nieboer, M.M., Middelkamp, S., de Ligt, J., Pregno, G., Giachino, D., Mandrile, G., Espejo Valle-Inclan, J., et al. (2017). Mapping and phasing of structural variation in patient genomes using nanopore sequencing. Nat. Commun. *8*, 1326.

European IVF-monitoring Consortium (EIM), European Society of Human Reproduction and Embryology (ESHRE), Calhaz-Jorge, C., De Geyter, C., Kupka, M.S., de Mouzon, J., Erb, K., Mocanu, E., Motrenko, T., Scaravelli, G., et al. (2017). Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE. Hum. Reprod. *32*, 1957–1973.

Feichtinger, M., Stopp, T., Göbl, C., Feichtinger, E., Vaccari, E., Mädel, U., Laccone, F., Stroh-Weigert, M., Hengstschläger, M., Feichtinger, W., et al. (2015). Increasing Live Birth Rate by Preimplantation Genetic Screening of Pooled Polar Bodies Using Array Comparative Genomic Hybridization. PLoS One *10*, e0128317.

Fonseka, K.G.L., and Griffin, D.K. (2011). Is there a paternal age effect for aneuploidy? Cytogenet. Genome Res. *133*, 280–291.

Franasiak, J.M., Forman, E.J., Hong, K.H., Werner, M.D., Upham, K.M., Treff, N.R., and Scott, R.T. (2014). The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil. Steril. *101*.

Greco, E., Minasi, M.G., and Fiorentino, F. (2015). Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts. N. Engl. J. Med. *373*, 2089–2090.

Hengstschläger, M., and Feichtinger, W. (2005). Die erste Präimplantationsdiagnostik in Österreich. Wien. Klin. Wochenschr. *117*, 725–727.

Hernandez-Nieto, C., Gayete-Lafuente, S., Alkon-Meadows, T., Lee, J., Luna-Rojas, M., Mukherjee, T., Copperman, A.B., and Sandler, B. (2021). Parental chromosomal heteromorphisms are not associated with an increased risk of embryo aneuploidy. JBRA Assist. Reprod. *25*, 575–580.

Hu, L., Liang, F., Cheng, D., Zhang, Z., Yu, G., Zha, J., Wang, Y., Xia, Q., Yuan, D., Tan, Y., et al. (2019). Location of Balanced Chromosome-Translocation Breakpoints by Long-Read Sequencing on the Oxford Nanopore Platform. Front. Genet. *10*, 1313.

Jain, M., Koren, S., Miga, K.H., Quick, J., Rand, A.C., Sasani, T.A., Tyson, J.R., Beggs, A.D., Dilthey, A.T., Fiddes, I.T., et al. (2018). Nanopore sequencing and assembly of a human genome with ultra-long

reads. Nat. Biotechnol. 2018 364 *36*, 338–345.

Kung, A., Munné, S., Bankowski, B., Coates, A., and Wells, D. (2015). Validation of next-generation sequencing for comprehensive chromosome screening of embryos. Reprod. Biomed. Online *31*, 760–769.

Li, H. (2018). Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics *34*, 3094–3100.

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., and 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics *25*, 2078–2079.

Lodge, C., and Herbert, M. (2020). Oocyte aneuploidy-more tools to tackle an old problem. Proc. Natl. Acad. Sci. U. S. A. *117*, 11850–11852.

Madjunkova, S., Sundaravadanam, Y., Antes, R., Abramov, R., Chen, S., Yin, Y., Zuzarte, P.C., Moskovtsev, S.I., Jorgensen, L.G.T., Baratz, A., et al. (2020). Detection of Structural Rearrangements in Embryos. N. Engl. J. Med. *382*, 2472–2474.

Margolis, C., Werner, M., and Jalas, C. (2021). Variant haplophasing by long-read sequencing: proof of concept in preimplantation genetic workup and an opportunity to distinguish balanced and normal embryos. Fertil. Steril. *116*, 668–669.

Mastenbroek, S., Twisk, M., van Echten-Arends, J., Sikkema-Raddatz, B., Korevaar, J.C., Verhoeve, H.R., Vogel, N.E.A., Arts, E.G.J.M., de Vries, J.W.A., Bossuyt, P.M., et al. (2007). In Vitro Fertilization with Preimplantation Genetic Screening. N. Engl. J. Med. *357*, 9–17.

Neumann, K., and Griesinger, G. (2020). An Economic Analysis of Aneuploidy Screening of Oocytes in Assisted Reproduction in Germany. Geburtshilfe Frauenheilkd. *80*, 172–178.

Neumann, K., Sermon, K., Bossuyt, P., Goossens, V., Geraedts, J., Traeger-Synodinos, J., Parriego, M., Schmutzler, A., van der Ven, K., Rudolph-Rothfeld, W., et al. (2020). An economic analysis of preimplantation genetic testing for aneuploidy by polar body biopsy in advanced maternal age. BJOG An Int. J. Obstet. Gynaecol. *127*, 710–718.

Oberle, A., Carli, L., Ennemoser, A., Hengstschläger, M., and Feichtinger, M. (2022). P-533   Single-cell long-read nanopore sequencing as a fast and cost-efficient method for aneuploidy detection and potentially PGT-A, a pre-clinical study. Hum. Reprod. *37*.

Pei, Z., Deng, K., Lei, C., Du, D., Yu, G., Sun, X., Xu, C., and Zhang, S. (2022). Identifying Balanced Chromosomal Translocations in Human Embryos by Oxford Nanopore Sequencing and Breakpoints Region Analysis. Front. Genet. *0*, 2723.

Petracchi, F., Colaci, D.S., Igarzabal, L., and Gadow, E. (2009). Cytogenetic analysis of first trimester pregnancy loss. Int. J. Gynaecol. Obstet. *104*, 243–244.

Piovesan, A., Pelleri, M.C., Antonaros, F., Strippoli, P., Caracausi, M., and Vitale, L. (2019). On the length, weight and GC content of the human genome. BMC Res. Notes *12*, 106.

Rubio, C., Bellver, J., Rodrigo, L., Castillón, G., Guillén, A., Vidal, C., Giles, J., Ferrando, M., Cabanillas, S., Remohí, J., et al. (2017). In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil. Steril. *107*, 1122–1129.

Sachdeva, K., Discutido, R., Albuz, F., Almekosh, R., and Peramo, B. (2017). Validation of Next-Generation Sequencer for 24-Chromosome Aneuploidy Screening in Human Embryos. Genet. Test. Mol. Biomarkers *21*, 674–680.

Scheinin, I., Sie, D., Bengtsson, H., van de Wiel, M.A., Olshen, A.B., van Thuijl, H.F., van Essen, H.F.,

Eijk, P.P., Rustenburg, F., Meijer, G.A., et al. (2014). DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. *24*, 2022–2032.

Scott, R.T., Upham, K.M., Forman, E.J., Zhao, T., and Treff, N.R. (2013). Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial. Fertil. Steril. *100*, 624–630.

Snider, A.C., Darvin, T., Spor, L., Akinwole, A., Cinnioglu, C., and Kayali, R. (2021). Criteria to evaluate patterns of segmental and complete aneuploidies in preimplantation genetic testing for aneuploidy results suggestive of an inherited balanced translocation or inversion. F&S Reports *2*, 72–79.

Treff, N.R., and Marin, D. (2021). The "mosaic" embryo: misconceptions and misinterpretations in preimplantation genetic testing for aneuploidy. Fertil. Steril. *116*, 1205–1211.

Ven, K. van der, Montag, M., and Ven, H. van der (2008). Polar Body Diagnosis – A Step in The Right Direction? Dtsch. Arztebl. Int.

Verpoest, W., Staessen, C., Bossuyt, P.M., Goossens, V., Altarescu, G., Bonduelle, M., Devesa, M., Eldar-Geva, T., Gianaroli, L., Griesinger, G., et al. (2018). Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. Hum. Reprod. *33*, 1767–1776.

Victor, A.R., Tyndall, J.C., Brake, A.J., Lepkowsky, L.T., Murphy, A.E., Griffin, D.K., McCoy, R.C., Barnes, F.L., Zouves, C.G., and Viotti, M. (2019). One hundred mosaic embryos transferred prospectively in a single clinic: exploring when and why they result in healthy pregnancies. Fertil. Steril. *111*, 280–293.

Viotti, M., Victor, A.R., Barnes, F.L., Zouves, C.G., Besser, A.G., Grifo, J.A., Cheng, E.-H., Lee, M.-S., Horcajadas, J.A., Corti, L., et al. (2021). Using outcome data from one thousand mosaic embryo transfers to formulate an embryo ranking system for clinical use. Fertil. Steril. *115*, 1212–1224.

Walters-Sen, L., Neitzel, D., Bristow, S.L., Mitchell, A., Alouf, C.A., Aradhya, S., and Faulkner, N. (2021). Experience analyzing >190,000 embryo trophectoderm biopsies using a novel FAST-SeqS PGT assay. Reprod. Biomed. Online.

Wei, S., Weiss, Z.R., Gaur, P., Forman, E., and Williams, Z. (2018). Rapid preimplantation genetic screening using a handheld, nanopore-based DNA sequencer. Fertil. Steril. *110*, 910-916.e2.

Wei, S., Djandji, A., Lattin, M.T., Nahum, O., Hoffman, N., Cujar, C., Kayali, R., Cinnioglu, C., Wapner, R., D'Alton, M., et al. (2022). Rapid Nanopore Sequencing-Based Screen for Aneuploidy in Reproductive Care. N. Engl. J. Med. *387*, 658–660.

Wong, K.M., van Wely, M., Verhoeve, H.R., Kaaijk, E.M., Mol, F., van der Veen, F., Repping, S., and Mastenbroek, S. (2021). Transfer of fresh or frozen embryos: a randomised controlled trial. Hum. Reprod. *36*, 998–1006.

Figure and Table Legends:

Figure 1: Study design including concordance rates found in this study. WGA: whole-genome amplification; PGT-A: preimplantation-genetic testing for aneuploidy; aCGH: array comparative-genomic hybridization; PPV and NPV: positive and negative predictive value.

Figure 2: Schematic overview of the nanopore sequencing workflow, including time measures for individual procedures, embedded in the clinical PGT-A workflow. Prorate sequencing time per sample was calculated according to medium sequencing time for 6 pooled samples. Separate sequencing of one sample can be shorter. ICSI: intra-cytoplasmatic sperm injection; PB: polar body; WGA: whole-genome amplification.

Figure 3: Occurrence of whole-chromosome aneuploidies in all 99 pooled PB samples. TP: true positive, FN: false negative, FP: false positive.

Figure 4: Example chromosomal distribution plots from automatically generated nanopore sequencing workflow. Quality values noise and MAPD are mapped for each chromosome and thresholds for the total sample (0.6 and 1.7, respectively) are highlighted in red. MAPD: Median of the Absolute values of all Pairwise Differences; noise: median standard deviation of normalised read counts within each segment.

Figure 5: Comparison of nanopore sequencing workflow with and without Endonuclease I digest. EN: Endonuclease I digest.

Table 1: Nanopore sequencing results in comparison with aCGH.

Figure 1:

Figure 2:

b) Polar Body Biopsy

10 min / sample

c) gDNA extraction and WGA

2.5 h / sample

- Polar body pooling
- Repli-g Single Cell Kit

d) Library Preparation

1 h / sample

- End preparation
- Ligation of barcode and sequencing adapters

e) Nanopore Sequencing and Real-Time Analysis

1 h / sample, 40 € / sample

- MinION Mk1C
- Flow cell (R9.4.1)
- Basecalling

f) Secondary Processing

5 min / sample

- Data cleaning
- Alignment
- Copy-number analysis

Current (pA)

Time (ms)

TG A A A GCGCT A A C A A A TGA TGCG

Alignment

FastQ

a) Oocyte pick-up and ICSI

i) Transfer of embryo from euploid oocyte

h) Selection for transfer

g) Same-day result for aneuploidy screening

Copy number

MAPD ➤ ⬅ Noise

Chromosome

PB1 PB2

Figure 3:

Figure 4:

Figure 5:

Table 1:

Sample	Ploidy Status			Chromosome Aberrations		
Number	aCGH	Nanopore	Concordance	aCGH	Nanopore	Concordance
Pb1	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb2	aneuploid	aneuploid	CONCORDANT	+22	+22	CONCORDANT
Pb3	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb4	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb5	aneuploid	aneuploid	CONCORDANT	-1	-1	CONCORDANT
Pb6	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb7	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb8	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb9	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb10	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb11	aneuploid	aneuploid	CONCORDANT	-4	-4	CONCORDANT
Pb12	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb13	aneuploid	aneuploid	CONCORDANT	-15	-15	CONCORDANT
Pb14	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb15	aneuploid	aneuploid	CONCORDANT	-10, +14	-10, +14	CONCORDANT
Pb16	aneuploid	aneuploid	CONCORDANT	+10, +X	+10, +X	CONCORDANT
Pb17	aneuploid	aneuploid	CONCORDANT	-14, +20	-14, +20	CONCORDANT
Pb18	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb19	aneuploid	aneuploid	CONCORDANT	+16, -18, -20	+16, -18, -20	CONCORDANT
Pb20	aneuploid	aneuploid	CONCORDANT	-7, +16	multiple	DISCORDANT
Pb21	aneuploid	aneuploid	CONCORDANT	+19, -21, -22	-21	DISCORDANT
Pb22	aneuploid	aneuploid	CONCORDANT	+12, -13, -16	+12, -13, -16	CONCORDANT
Pb23	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb24	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb25	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb26	aneuploid	aneuploid	CONCORDANT	-16	-16	CONCORDANT
Pb27	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb28	aneuploid	aneuploid	CONCORDANT	-6, -12	-6, -12	CONCORDANT
Pb29	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb30	aneuploid	aneuploid	CONCORDANT	+11, +15, +22	+11, +15, +22	CONCORDANT
Pb31	aneuploid	aneuploid	CONCORDANT	-17	-17	CONCORDANT
Pb32	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb33	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb34	aneuploid	aneuploid	CONCORDANT	-13, -15, -21	-13, -15, -21	CONCORDANT
Pb35	aneuploid	aneuploid	CONCORDANT	-22	-22	CONCORDANT
Pb36	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb37	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb38	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb39	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb40	aneuploid	aneuploid	CONCORDANT	+4	+4	CONCORDANT
Pb41	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb42	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb43	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb44	aneuploid	aneuploid	CONCORDANT	+15	+15	CONCORDANT
Pb45	aneuploid	aneuploid	CONCORDANT	+16, -19	+16, -19	CONCORDANT
Pb46	aneuploid	euploid	DISCORDANT	+22	-	DISCORDANT
Pb47	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb48	euploid	not evaluable	EXCLUDED	-		EXCLUDED
Pb49	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb50	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb51	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb52	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb53	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb54	aneuploid	aneuploid	CONCORDANT	-9, -15	-9, -15	CONCORDANT
Pb55	aneuploid	aneuploid	CONCORDANT	-17, -18	-17, -18	CONCORDANT
Pb56	aneuploid	aneuploid	CONCORDANT	-16	-16	CONCORDANT
Pb57	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb58	aneuploid	aneuploid	CONCORDANT	-13, -14, +17	multiple	DISCORDANT
Pb59	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb60	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb61	not evaluable	euploid	EXCLUDED		-	EXCLUDED
Pb62	aneuploid	euploid	DISCORDANT	+19	-	DISCORDANT
Pb63	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb64	aneuploid	aneuploid	CONCORDANT	+4	+4	CONCORDANT
Pb65	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb66	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb67	aneuploid	aneuploid	CONCORDANT	+12, -15	+12, -15	CONCORDANT
Pb68	aneuploid	aneuploid	CONCORDANT	+2	+2	CONCORDANT
Pb69	aneuploid	aneuploid	CONCORDANT	+6, -18	+6, -18	CONCORDANT
Pb70	aneuploid	aneuploid	CONCORDANT	-16, -22	-16, -22	CONCORDANT
Pb71	aneuploid	aneuploid	CONCORDANT	+11, +16, -17	+11, +16, -17	CONCORDANT
Pb72	aneuploid	aneuploid	CONCORDANT	-19	-19	CONCORDANT
Pb73	aneuploid	aneuploid	CONCORDANT	+4, -20	+4, -20	CONCORDANT
Pb74	aneuploid	aneuploid	CONCORDANT	-16, +21	-16, +21	CONCORDANT
Pb75	aneuploid	aneuploid	CONCORDANT	+16, +22	+16, +22	CONCORDANT
Pb76	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb77	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb78	aneuploid	aneuploid	CONCORDANT	+17, -22	+17, -22	CONCORDANT
Pb79	aneuploid	aneuploid	CONCORDANT	+18	+18	CONCORDANT
Pb80	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb81	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb82	aneuploid	aneuploid	CONCORDANT	+9, -13	+9, -13	CONCORDANT
Pb83	aneuploid	aneuploid	CONCORDANT	+16, -19	+16, -19	CONCORDANT
Pb84	aneuploid	aneuploid	CONCORDANT	+1	+1	CONCORDANT
Pb85	aneuploid	euploid	DISCORDANT	-16	-	DISCORDANT
Pb86	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb87	aneuploid	aneuploid	CONCORDANT	+20	+20	CONCORDANT
Pb88	aneuploid	aneuploid	CONCORDANT	-17	-17	CONCORDANT
Pb89	aneuploid	aneuploid	CONCORDANT	+22	+22	CONCORDANT
Pb90	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb91	aneuploid	aneuploid	CONCORDANT	-2, +6	-2, +6	CONCORDANT
Pb92	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb93	aneuploid	aneuploid	CONCORDANT	+1, -16, +19	+1, -16	DISCORDANT
Pb94	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb95	not evaluable	euploid	EXCLUDED		-	EXCLUDED
Pb96	aneuploid	aneuploid	CONCORDANT	+11, -16, +19	+11, -16	DISCORDANT
Pb97	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb98	aneuploid	aneuploid	CONCORDANT	-4	-4	CONCORDANT
Pb99	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb100	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb101	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb102	euploid	euploid	CONCORDANT	-	-	CONCORDANT